EquivaBone is now additionally indicated for use in posterolateral spine fusion, combining the certified osteoinductivity of DBM with the handling and hard setting characteristics of Etex calcium phosphate osteoconductive scaffold.
The clearance also allows EquivaBone to be mixed with autologous blood to create a viscous putty can then be molded and packed or injected into a defect.
Read Etex’s release on FDA approval of EquivaBone.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
